Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional bevacizumab after surgical debulking for recurrent laryngeal papillomatosis in children
IRCT20251230068497N1Phase 4Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Laryngeal papilloma (RRP), sponsored by Iran University of Medical Sciences. Primary endpoints: Recurrence frequency and Time to recurrence. Started Jan 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
Laryngeal papilloma (RRP)
Beyond the preview
Go deeper on IRCT20251230068497N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251230068497N1.